| Date | Title | Description |
| 13.01.2023 | California-based biotech firm Alume Biosciences raises USD 13 million in Series B funding | LA JOLLA, Calif., Jan. 10, 2023 Alume Biosciences, Inc. has raised USD 13 million in Series B funding to push Bevonescein (ALM-488), its flagship product, through Phase 3 clinical trials. Alume, a pioneer in nerve-targeted diagnostics and t... |
| 11.01.2023 | Alume Biosciences Raises $13M in Series B Funding | Alume Biosciences, a La Jolla, CA-based company in the field of nerve-targeted diagnostics and therapeutics, raised $13M in Series B funding.
The backers were undisclosed.
The company intends to use the funds to advance its lead candidate, ... |
| 11.01.2023 | Alume BioSciences completes a $13M series b funding round to advance their leading candidate through Phase 3 clinical trials | - |
| 10.01.2023 | Alume Biosciences Secures $13M Series B Round |
LA JOLLA, CA, Alume Biosciences has secured $13 million in Series B financing to advance its lead candidate, Bevonescein (ALM-488), in Phase 3 clinical trials.
>> Click here for more funding data on Alume Biosciences
>> To e... |
| 15.12.2020 | Alume Receives SBIR Phase II Grant from the NIH to Support Clinical Trial of ALM-488 to Highlight Nerves in Patients Undergoing Head & Neck Surgery | |
| 04.05.2020 |
Alume Biosciences Gets $5.5M
| La Jolla-based biotechnology startup Alume Biosciences announced that it has raised $5.5M in a Series A funding round, to go towards its products. According to Alume, the funding came from angel investors, including co-founder Chrysa Mineo ... |
| 01.05.2020 | Alume Biosciences CLoses $5.5M Series A Financing Round | Alume Biosciences, Inc., a La Jolla, Calif.-based biotechnology company developing nerve-targeted pharmaceuticals for surgical and therapeutic use, completed a Series A funding in the amount of $5.5m.
Backers included co-founder Chrysa Mine... |
| - | Alume Biosciences | “Alume Biosciences – Precision Surgery. Illuminating Nerves, Preserving Function” |
